Saturday 17 October 2026
Export CBLL’s income statement to Excel — free account
CeriBell, Inc.
CBLL Healthcare Medical Devices
CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024. In the quarter to June 2026, revenue grew 32.5%, EPS fell 34.2%, free cash flow fell 68.6% and total debt rose 1.52%, each against the same quarter a year earlier.
25.04
2.60
−9.41%
Follow CBLL
CeriBell, Inc. (CBLL) P/E ratio
CeriBell, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 7 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PRCT PROCEPT BioRobotics Corporation compare | n/m |
| AORT Artivion, Inc. compare | n/m |
| CBLL CeriBell, Inc. | n/m |
| IART Integra LifeSciences Holdings Corporation compare | n/m |
| LMRI Lumexa Imaging Holdings, Inc. compare | n/m |
| ENOV Enovis Corporation compare | n/m |
| TNDM Tandem Diabetes Care, Inc. compare | n/m |
| BVS Bioventus Inc. compare | 16.4× |
| IRMD iRadimed Corporation compare | 48.5× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)